低场磁共振引导放疗中ERITCP预测直肠癌病理完全缓解的外部验证
多机构回顾性研究纳入52例局部晚期直肠癌新辅助放化疗患者,在0.35 T磁共振引导放疗下验证基于肿瘤控制概率的早期消退指数ERITCP对病理完全缓解的预测价值,并评估不同生物有效剂量水平下的预测时机。结果显示ERITCP准确预测47/52例,BED=25 Gy时预测性能最佳,且对观察者间变异稳健。
要点
- ERITCP在0.35 T磁共振引导放疗中预测pCR准确率90%,AUC=0.93(BED=25 Gy)。
- ERITCP对观察者间变异稳健,组内相关系数0.99。
- BED=25 Gy为ERITCP预测pCR的最佳生物有效剂量水平。
核心结论
- ERITCP在低场磁共振引导放疗背景下作为直肠癌pCR预测指标的有效性和稳健性得到验证。
- BED=25 Gy被确定为进行pCR预测的最佳生物有效剂量水平。
研究设计与样本
- 多机构回顾性研究纳入52例接受新辅助放化疗的局部晚期直肠癌患者。
- 每例患者在模拟定位和每个治疗日采集0.35 T T2/T1加权磁共振图像。
- 大体肿瘤体积按国际辐射单位与测量委员会第83号报告指南勾画。
- 按原始定义计算BED=25 Gy时的残余肿瘤体积得出ERITCP,另在BED为13、21、32、40、46、54、59和67 Gy时计算ERI。
- 用受试者工作特征曲线评估不同ERI指标的预测性能,并用2名操作者计算的组内相关系数评估ERITCP对观察者间变异的稳健性。
主要发现
- ERITCP正确预测47/52例,准确率90%,灵敏度86%,特异度92%,阴性预测值95%,阳性预测值80%。
- 不同BED水平分析显示,BED=25 Gy时预测性能最佳,曲线下面积=0.93。
- ERITCP对观察者间变异稳健,组内相关系数=0.99。
关键数值与推荐
- ERITCP在BED=25 Gy时预测pCR:准确率90%,灵敏度86%,特异度92%,阴性预测值95%,阳性预测值80%,AUC=0.93。
- ERITCP观察者间变异稳健性:组内相关系数=0.99。
- 最佳预测时机为BED=25 Gy。
临床怎么用
- 在低场磁共振引导放疗中,可基于BED=25 Gy时的ERITCP预测局部晚期直肠癌患者的pCR,辅助临床决策。
- ERITCP对观察者间变异稳健,支持其在不同操作者间的可重复应用。
局限性
- 研究仅针对0.35 T低场磁共振引导放疗条件下的验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor control probability (TCP)-based early regression index (ERITCP) is a radiobiological parameter that showed promising results in predicting pathologic complete response (pCR) on T2-weighted 1.5 T magnetic resonance (MR) images of patients with locally advanced rectal cancer. This study aims to validate the ERITCP in the context of low-tesla MR-guided radiation therapy, using images acquired with different magnetic field strength (0.35 T) and image contrast (T2/T1). Furthermore, the optimal timing for pCR prediction was estimated, calculating the ERI index at different biologically effective dose (BED) levels. METHODS AND MATERIALS: Fifty-two patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation therapy were enrolled in this multi-institutional retrospective study. For each patient, a 0.35 T T2/T1-weighted MR image was acquired during simulation and on each treatment day. Gross tumor volume was contoured according to International Commission on Radiation Units Report 83 guidelines. According to the original definition, ERITCP was calculated considering the residual tumor volume at BED = 25 Gy. ERI was also calculated in correspondence with several BED levels: 13, 21, 32, 40, 46, 54, 59, and 67. The predictive performance of the different ERI indices were evaluated in terms of receiver operating characteristic curve. The robustness of ERITCP with respect to the interobserver variability was also evaluated considering 2 operators and calculating the intraclass correlation index. RESULTS: Fourteen patients showed pCR. ERITCP correctly 47 of 52 cases (accuracy = 90%), showing good results in terms of sensitivity (86%), specificity (92%), negative predictive value (95%), and positive predictive value (80%). The analysis at different BED levels shows that the best predictive performance is obtained when this parameter is calculated at BED = 25 Gy (area under the curve = 0.93). ERITCP results are robust with respect to interobserver variability (intraclass correlation index = 0.99). CONCLUSIONS: This study confirmed the validity and the robustness of ERITCP as a pCR predictor in the context of low-tesla MR-guided radiation therapy and indicate 25 Gy as the best BED level to perform predictions.
引用
- Cusumano D, Boldrini L, Yadav P, et al. External Validation of Early Regression Index (ERITCP) as Predictor of Pathologic Complete Response in Rectal Cancer Using Magnetic Resonance-Guided Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32758641. doi:10.1016/j.ijrobp.2020.07.2323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。